Onconetix (ONCO) Change in Receivables (2024 - 2026)
Onconetix (ONCO) posted quarterly Change in Receivables of -$270735.0 for Q1 2026, down 2764.01% year-over-year from $10162.7 in Q1 2025, and down 192.11% quarter-over-quarter from $293929.0 in Q4 2025.
Onconetix (ONCO) Change in Receivables (2024 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Change in Receivables for 3 consecutive years, with -$270735.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables fell 2764.01% year-over-year to -$270735.0; the TTM figure through Mar 2026 stood at $7403.0 (up 103.05% YoY), while the FY2025 annual figure was $268685.0, up 330.28% from the prior year.
- Change in Receivables eased to -$270735.0 in Q1 2026 per ONCO's latest filing, from $293929.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $293929.0 in Q4 2025 and bottomed at -$270735.0 in Q1 2026.
- Historically, Change in Receivables has averaged -$13191.8 across 3 years, with a median of -$9559.0 in 2025.
- Annual changes were most pronounced in 2025 — Change in Receivables jumped 534.83% — and 2026, when it plunged 2764.01%.
- Onconetix's Change in Receivables stood at -$67597.0 in 2024, then surged by 534.83% to $293929.0 in 2025, then plunged by 192.11% to -$270735.0 in 2026.
- Business Quant data shows ONCO's Change in Receivables at -$270735.0 in Q1 2026, $293929.0 in Q4 2025, and -$9559.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | -41,450.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -41,450.00 |
| Jun 30, 2026 | -41,450.00 |
| Mar 31, 2026 | -270,735.00 |
| Mar 31, 2026 | -270,735.00 |
| Dec 31, 2025 | 293,929.00 |
| Dec 31, 2025 | 293,929.00 |
| Sep 30, 2025 | -9,559.00 |
| Sep 30, 2025 | -9,559.00 |
| Jun 30, 2025 | -6,232.00 |
| Jun 30, 2025 | -6,232.00 |
| Mar 31, 2025 | -9,453.00 |
| Mar 31, 2025 | -9,453.00 |
| Dec 31, 2024 | -67,597.00 |
| Dec 31, 2024 | -67,597.00 |
| Sep 30, 2024 | -80,580.00 |
| Sep 30, 2024 | -80,580.00 |
| Jun 30, 2024 | -85,262.00 |
| Jun 30, 2024 | -85,262.00 |
| Mar 31, 2024 | 116,763.00 |
| Mar 31, 2024 | 116,763.00 |